# Breakthrough Trials: Everyday Drugs Combat Alzheimer's!

Newsy: Alzheimer’s News Weekly
Published: 2026-03-02T14:30:00.254Z
Source: https://newsyai.com/edition/7659c11d-99e0-4d83-9350-5d19d45709c8
Archive: https://newsyai.com/newsy/2e52bc28-656d-42e4-981f-28a7be9142df.md

---

# Alzheimer’s Treatment Briefing
**Coverage period: February 27–March 2, 2026**

Below are this week’s most meaningful, truly **new** developments, ranked by impact on treatment and access.[[1]](https://www.kjzz.org/science/2026-03-02/barrow-launches-2-new-clinical-trials-aimed-at-fighting-alzheimers-disease)[[2]](https://www.medscape.com/viewarticle/therapeutic-research-alzheimers-disease-what-new-2026a10006bo)

1. **Two new drug trials launch using everyday medicines to fight brain inflammation and reset immunity**
   - **Overview**  
     Barrow Neurological Institute started two fresh trials on March 2 testing old drugs in new ways for Alzheimer's. One uses a bone cancer medicine to cut down swelling in the brain for people with early memory loss from Alzheimer's (ages 50-90). The other tests a long-used multiple sclerosis drug to retrain the body's defense cells, open even to those already on brain-protein-clearing shots like Leqembi.[[1]](https://www.kjzz.org/science/2026-03-02/barrow-launches-2-new-clinical-trials-aimed-at-fighting-alzheimers-disease) ([KJZZ](https://www.kjzz.org/science/2026-03-02/barrow-launches-2-new-clinical-trials-aimed-at-fighting-alzheimers-disease))
   - **Why this matters**  
     Swelling and overactive defense cells damage the brain in Alzheimer's. Repurposing safe, approved drugs speeds help to patients faster than waiting years for brand-new ones, adding options to current treatments.

2. **Next-gen brain-protein clearer trontinemab clears plaques fast with few side effects; phase 3 trial underway**
   - **Overview**  
     At the Alzheimer Congress on March 2, data showed Roche's trontinemab—a lab-made body defender—removed nearly all sticky harmful protein buildup in the brain after 6 months in early trials. It also cut signs of twisted nerve proteins and slowed thinking decline hints, with brain swelling side effects under 5%. A big phase 3 test is now running to prove it helps daily life.[[2]](https://www.medscape.com/viewarticle/therapeutic-research-alzheimers-disease-what-new-2026a10006bo) ([Medscape](https://www.medscape.com/viewarticle/therapeutic-research-alzheimers-disease-what-new-2026a10006bo))
   - **Why this matters**  
     Current plaque removers slow decline modestly but have risks. Trontinemab's strong cleanup and safety could mean better slowdown of symptoms, expanding choices soon.

3. **Expert roadmap maps all-in-one attack on aging, body health, genes plus brain proteins**
   - **Overview**  
     A February 27 review lays out a full plan to mix treatments hitting not just brain proteins but also body-wide issues like poor blood sugar control, high blood pressure, gut problems, cell aging, and gene risks (like editing bad genes). It pushes lab-grown mini-brains for fast testing and early blood signs for custom care.[[3]](https://www.eurekalert.org/news-releases/1118098) ([EurekAlert](https://www.eurekalert.org/news-releases/1118098))
   - **Why this matters**  
     Single-target drugs fall short. This combo blueprint could fix root causes together, turning Alzheimer's from unstoppable to preventable or controllable.

4. **Overlooked short protein piece p3 may fuel brain damage, urging rethink of plaque drugs**
   - **Overview**  
     On February 27, research revealed p3—a tiny harmless-seeming protein cut from the same source as the main sticky plaques—clumps even faster and might team up with plaques to harm nerves. Current plaque-target drugs like lecanemab ignore it, possibly limiting their wins.[[4]](https://news.ucsc.edu/2026/02/neglected-peptide-p3-alzheimers) ([UCSC News](https://news.ucsc.edu/2026/02/neglected-peptide-p3-alzheimers))
   - **Why this matters**  
     Blaming only plaques missed this partner-in-crime. Targeting p3 too could boost drug power and explain why trials underwhelm, guiding smarter next steps.

5. **Natural fruit compound α-amyrin ramps up brain cell cleanup to fight twisted proteins**
   - **Overview**  
     February findings show α-amyrin—from plants—boosts brain cells' self-cleaning to break down harmful twisted proteins (tau) that spread damage, easing symptoms in lab models.[[5]](https://www.alzforum.org/news/research-news/fruity-finding-does-amyrin-boost-autophagy-thwart-tau-pathology) ([Alzforum](https://www.alzforum.org/news/research-news/fruity-finding-does-amyrin-boost-autophagy-thwart-tau-pathology))
   - **Why this matters**  
     Natural helpers like this offer safe add-ons to clear tau alongside plaque drugs, filling gaps in today's toolbox for fuller protection.

## What this means for care right now
- **Join trials early**  
  Repurposed drugs like in Barrow trials mean quick access—check eligibility for inflammation or immunity boosts alongside standards.[[1]](https://www.kjzz.org/science/2026-03-02/barrow-launches-2-new-clinical-trials-aimed-at-fighting-alzheimers-disease)
- **Watch pipeline stars**  
  Trontinemab eyes phase 3 wins; pair with multi-target ideas for combos beating single drugs.[[2]](https://www.medscape.com/viewarticle/therapeutic-research-alzheimers-disease-what-new-2026a10006bo)[[3]](https://www.eurekalert.org/news-releases/1118098)
- **Rethink basics**  
  Screen gut health, blood sugar, aging signs—low-cost tweaks amplify drugs; discuss p3-aware futures.[[4]](https://news.ucsc.edu/2026/02/neglected-peptide-p3-alzheimers)
- **Explore naturals cautiously**  
  α-Amyrin hints at supplements aiding cleanup—talk to docs for safe trials.[[5]](https://www.alzforum.org/news/research-news/fruity-finding-does-amyrin-boost-autophagy-thwart-tau-pathology)

## Sources
- Barrow trials (March 2, 2026), [KJZZ](https://www.kjzz.org/science/2026-03-02/barrow-launches-2-new-clinical-trials-aimed-at-fighting-alzheimers-disease).[[1]](https://www.kjzz.org/science/2026-03-02/barrow-launches-2-new-clinical-trials-aimed-at-fighting-alzheimers-disease)
- Congress updates incl. trontinemab/bepranemab (March 2, 2026), [Medscape](https://www.medscape.com/viewarticle/therapeutic-research-alzheimers-disease-what-new-2026a10006bo).[[2]](https://www.medscape.com/viewarticle/therapeutic-research-alzheimers-disease-what-new-2026a10006bo)
- Multi-target roadmap (Feb 27, 2026), *Science China Life Sciences*, [EurekAlert](https://www.eurekalert.org/news-releases/1118098).[[3]](https://www.eurekalert.org/news-releases/1118098)
- p3 peptide (Feb 27, 2026), [UCSC News](https://news.ucsc.edu/2026/02/neglected-peptide-p3-alzheimers).[[4]](https://news.ucsc.edu/2026/02/neglected-peptide-p3-alzheimers)
- α-Amyrin tau study (Feb ~28, 2026), [Alzforum](https://www.alzforum.org/news/research-news/fruity-finding-does-amyrin-boost-autophagy-thwart-tau-pathology).[[5]](https://www.alzforum.org/news/research-news/fruity-finding-does-amyrin-boost-autophagy-thwart-tau-pathology)

If a week brings few blockbuster trial results, focus stays on building blocks for better care.
